美國政府向輝瑞訂購1,000萬劑新冠口服藥
輝瑞(PFE.US)公佈,與美國政府簽訂1,000萬劑新冠藥品供應協議,涉52.9億美元,交易規模較美國政府與藥廠默沙東(MRK.US)早前簽訂協議高出約一倍。但以每劑價格計,輝瑞供應的新冠藥爲530美元,低過默沙東的700美元。
兩間藥廠已經向美國食品及藥物管理局(FDA)提交緊急使用授權(EAU)申請,但仍未獲準準。輝瑞早前公佈,該藥物在防止高危人羣住院或死亡方面有89%的效果,獲批緊急使用授權後將盡快向當局交付藥品,並預期下月底可生產出18萬劑藥品,明年底前至少生產5,000萬劑。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.